WO2000054593A1

WO2000054593A1 - Iodine preparation compositon

Info

Publication number: WO2000054593A1
Application number: PCT/EP2000/002194
Authority: WO
Inventors: Dave Parsons; Elizabeth Jacques; Philip Bowler
Original assignee: Bristol-Myers Squibb Company
Priority date: 1999-03-12
Filing date: 2000-03-13
Publication date: 2000-09-21
Also published as: CA2364027A1; US7014871B1; JP2002539140A; ES2209862T3; BR0008952A; ATE254851T1; GB9905663D0; CA2364027C; EP1158859A1; NZ513991A; DE60006788T2; AU4104900A; EP1158859B1; AU766031B2; DE60006788D1

Abstract

An iodine preparation composition suitable for use on wounds comprising an iodide source, an oxidant and a buffer characterised in that the iodide is held separately from the oxidant until the point of use, and that the buffer is capable of maintaining the pH of the composition at between pH 4.5 and pH 6 so that iodine is generated at a physiologically acceptable dose rate.

Description

Iodine Preparation Composition

This invention relates to an antimicrobial composition which can be applied to

wounds, cuts, abrasions or burns for the prevention or treatment of infections.

More particularly the invention relates to a composition capable of providing

effective antimicrobial activity while at the same time avoiding wound and skin

irritation and retardation of wound healing.

Topical antimicrobial materials and preparations containing them have long been

recognised as important parts of antisepsis of intact skin and wounds. Iodine has

been recognized as an antimicrobial agent with effectiveness against a wide range

of micro-organisms. There are however several barriers to making an effective

antimicrobial composition for application to wounds based on iodine. One

problem is that iodine tends to react with organic materials found in the wound

other than the intended microbial targets. This means that to be effective, iodine

needs to be included at high levels such as 0.9% by weight, as described in

"Handbook of Wound Dressings" edited by Stephen Thomas, 1994 Journal of

Wound Care. . At such levels and with continued use iodine may have

undesirable local side effects such as cell toxicity, hypersensitivity reactions, skin

staining, and unpleasant odour and systemic adverse effects such as metabolic

acidosis and impairment of renal function. For this reason application of iodine

is recommended at levels below 1.35g in one week. A further problem is that iodine has a relatively short shelf life when in aqueous

solution meaning either that compositions which include water need to be freshly

prepared before each application or again that iodine is included at high levels.

These factors limit product form.

In the past these problems with iodine have sought to be addressed by the use of

iodophors which act as a release mechanism for iodine. lodophors are readily

dissociable, loose complexes of iodine with polymers or surfactants. Iodophor

compositions are not best suited to use on wounds because when applied to a

wound, all iodine present in the composition is readily available for reaction and

therefore the adverse reactions associated with high levels of iodine are not

necessarily avoided.

There thus exists a need for a composition which delivers iodine to a wound at

a rate which is high enough to provide effective antisepsis but which is low

enough

to avoid the problems of adverse reactions associated with high levels of iodine.

GB-B-2276546 to Diversey relates to improved iodophors which are prepared at

the point of use. The composition comprises an iodide source, an oxidant and an

acid source, the oxidant becoming active only when the composition is dissolved

in an aqueous medium. The composition is said to overcome the stability

problems associated with producing teat dip/spray iodine formulations for use in the control of bovine mastitis. The rate of generation of iodine needed for these

topical formulations for use on intact skin far exceeds that tolerable to a wound.

In these compositions such high levels of iodine are generated that a hydrotrope

must be included to prevent the iodine from crystallising. In addition, iodine has

a complex chemistry in aqueous solutions and exists in a number of equilibria.

At high iodine concentrations in the presence of iodide there is a strong tendency

for the tri-iodide ion to form. We believe that this ion has very little

antimicrobial activity but can still be absorbed with the risk of systemic toxicity.

We have found that it is possible to prepare a composition which is capable of

generating iodine at a rate and level that makes it suitable for use in wounds.

This is achieved by separating certain of the ingredients and controlling the

kinetics of the generation of iodine through the manipulation of pH.

Accordingly the present invention provides an iodine preparation composition

suitable for use on wounds comprising an iodide source, an oxidant and a buffer

characterised in that the oxidant is held separately from the iodide until the point

of use, and that the buffer is capable of maintaining the pH of the composition at

between pH 4.5 and pH 6 so that iodine is generated at a physiologically

acceptable and efficacious rate.

The invention allows the preparation of compositions generating a low but

effective iodine level for example up to about 2000μg per g of composition per hour, preferably in the range of 5μg per g of composition per hour to 1500μg per

g of composition per hour, more preferably in the range 50μg per g of

composition per hour to lOOOμg per g of composition per hour so that the amount

of free iodine available for antisepsis at any time is at least 0.001%.

The compositions of the invention are preferably formulated to generate the

above levels of iodine over a period of about 3 days.

The pH of the composition of the invention is generally below 5.8. We have

found that if the pH is greater than about 6, the rate of production of iodine by

reaction of the oxidising agent with iodide ions is too low to balance any losses

of iodine by reaction with the organic matter. We have found that it is generally

desired that the pH of the compositions is not below about 4.5 as otherwise there

is a danger that the rate of oxidation of the iodide ions will be too fast with the

result that the composition could become toxic.

The desired pH of the compositions may be achieved by incorporating buffering

agents therein. Examples of buffering agents which may be included are citric

acid/disodium hydrogen phosphate, citric acid/sodium citrate, acetic acid/sodium

acetate. The buffering agent may conveniently be present in an amount of about

2% to 10%), preferably about 4% to 6% by weight and particularly about 5% by

weight so as to provide an isotonic composition. The amount of oxidant in the composition is tailored to provide a stoichiometric

match with iodide. Preferably the oxidant is iodate and is provided in a molar

ratio of 1 :5 with iodide. In this way the iodide present in the composition fully

reacts with all the oxidant. To provide the levels and rate of production of iodine

in the range described above it is desirable to include up to 2% by weight of

iodide, preferably, from 0.2 % to 2 %> by weight of iodide. Iodide and iodate are

preferably present as sodium salts although other usual counter ions may be used.

Convenient forms of administration of the composition include aqueous gels,

films, creams, tablets and capsules.

The following examples are illustrative of the present invention.

Example 1.

Gel A Weight g

Hydroxyethyl cellulose 30.00

Propylene Glycol 150.00

Na₂HPO₄ 35.61

Citric Acid 21.01

Potassium Iodate 1.124

Water 762.256

Gel B Weight in g Hydroxy ethyl cellulose 30.0

Propylene Glycol 150.0

Potassium Iodide 4.36

Water 815.64

Gel A was made by dissolving the buffer salt in a water/propylene glycol mix and

then adding the iodate. When the solution is clear the hydroxy ethyl cellulose is

added and mixed until gelation is complete. Gel B was made by dissolving

iodide in a water/propylene glycol mix. Hydroxyethyl cellulose was added to this

mixture and mixed until gelation was complete.

The gels were packaged in separate syringes which were bound together with

their nozzles fitted into a Y-shaped connecter. The contents were sterilised by

autoclaving at 121 C for 15 minutes. Simultaneous depression of the plungers

allows the gels to be co-extruded and allows the gels to react while being

dispensed into a wound. The co-extrusion of the gels results in a product

producing approximately lOOμg per g of composition per hour at a pH of about

5.4. The composition generated a greater than 5 log kill of S aureous (NCIMB

9518) which is regarded as being an acceptable level of antimicrobial activity.

Example 2

Film A Hydroxypropylcellulose 16

Propylene Glycol 4

Potassium Iodate 0.1124

Sodium phosphate 1.7805

Citric acid 1.0505

Water 77.0566

Film B

Hydroxypropylcellulose 16

Propylene Glycol 4

Potassium Iodide 0.436

Water 79.564

The films are produced by knife over roller coating of aqueous solution onto an

inert carrier followed by drying at a temperature not exceeding 100 C and

sterilised by gamma irradiation.

The films may be cut into rectangles and added to a wound whereupon they

dissolve in the wound fluid and reaction takes place.

Claims

1. An iodine preparation composition suitable for use on wounds

comprising an iodide source, and oxidant and a buffer characterised in that the

iodide is held separately from the oxidant until the point of use, and that the

buffer is capable of maintaining the pH of the composition at between pH 4.5 and

pH 6 so that iodine is generated at a physiologically acceptable dose and rate.

2. An iodine preparation composition suitable for use on wounds

comprising an iodide source, an oxidant and a buffer for simultaneous or

sequential use in the treatment of sepsis in wounds.

3. Use of an iodine preparation composition comprising an iodide source, an

oxidant and a buffer for simultaneous or sequential use in the treatment of sepsis

in wounds.

4. An iodine preparation composition as claimed in claim 1 characterised in

that the composition is capable of generating from 5μg of iodine per g of

composition per hour to 1500μg of iodine per g of composition per hour,

preferably 1 OOμg of iodine per g of composition per hour.